Bioavailability and saturation of the presystemic metabolism of oral lorcainide therapy initiated in three different dose regimens

Eur J Clin Pharmacol. 1983;24(4):517-9. doi: 10.1007/BF00609895.

Abstract

The feasibility of giving a supplementary starting dose of the antiarrhythmic drug lorcainide, in order to minimalize the impact of the extensive, but saturable first-pass metabolism, was evaluated. Twenty-five adult patients were given 100 mg lorcainide tablets according to one of 3 different dosage schedules: Eight patients took one tablet at 0, 12 and 24 h, 8 took 1 tablet at 0, 1, 12 and 24 h and 9 took 1 tablet at 0, 2, 12 and 24 h. Levels of lorcainide and its metabolite, nor-lorcainide, during treatment were determined by gas-liquid chromatography. The results show that giving a second tablet 1 or 2 h after the first may produce faster saturation of the pre-systemic metabolism of lorcainide in the liver.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Benzeneacetamides*
  • Biological Availability
  • Biotransformation
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Middle Aged
  • Piperidines / administration & dosage*
  • Piperidines / metabolism

Substances

  • Benzeneacetamides
  • Piperidines
  • lorcainide